Literature DB >> 19775838

Vaccines and preterm neonates: why, when, and with what.

Susanna Esposito1, Domenico Serra, Laura Gualtieri, Laura Cesati, Nicola Principi.   

Abstract

This review analyses what is known concerning the immune response of preterm (PTIs) and low birth weight infants (LBWIs) to widely used vaccines, the protection they receive from routine immunisation, and the safety and tolerability of the vaccines themselves. It shows why PTIs and LBWIs should be vaccinated using the same schedules as those usually recommended for full-term infants (FTIs), except in the case of hepatitis B vaccine, whose schedule should be repeated in infants who received the first dose during the first days of life when they weighed less than 2000 g because of their reduced immune response. Vaccines are immunogenic, safe and well tolerated in PTIs and LBWIs, in whom early active immunisation is particularly important because they are among the most vulnerable subjects for pediatric infectious diseases. It is therefore essential to make every effort to convince pediatricians and parents that compliance with these recommendations will not cause any clinical problems.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19775838     DOI: 10.1016/j.earlhumdev.2009.08.011

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  9 in total

1.  Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts.

Authors:  A Orsi; C Azzari; E Bozzola; G Chiamenti; G Chirico; S Esposito; F Francia; P Lopalco; R Prato; R Russo; A Villani; E Franco
Journal:  J Prev Med Hyg       Date:  2018-06-01

2.  Vaccine schedule compliance among very low birth weight infants in Lima, Peru.

Authors:  Theresa J Ochoa; Alonso Zea-Vera; Rossana Bautista; Carmen Davila; José Antonio Salazar; Carlos Bazán; Luis López; Lucie Ecker
Journal:  Vaccine       Date:  2014-11-21       Impact factor: 3.641

Review 3.  Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly.

Authors:  Tobias R Kollmann; Ofer Levy; Ruth R Montgomery; Stanislas Goriely
Journal:  Immunity       Date:  2012-11-16       Impact factor: 31.745

4.  Alkylglycerols modulate the proliferation and differentiation of non-specific agonist and specific antigen-stimulated splenic lymphocytes.

Authors:  Linxi Qian; Mingshun Zhang; Shengmei Wu; Yan Zhong; Eric Van Tol; Wei Cai
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

5.  Are pre-terms born timely and right immunized? Results of an Italian cohort study.

Authors:  Nicola Laforgia; Antonio Di Mauro; Francesco Paolo Bianchi; Federica Di Mauro; Andrea Zizzi; Manuela Capozza; Silvia Intini; Maria Serena Gallone; Silvio Tafuri
Journal:  Hum Vaccin Immunother       Date:  2018-02-15       Impact factor: 3.452

6.  Adjuvant Effect of Bacille Calmette-Guérin on Hepatitis B Vaccine Immunogenicity in the Preterm and Term Newborn.

Authors:  Annette Scheid; Francesco Borriello; Carlo Pietrasanta; Helen Christou; Joann Diray-Arce; Matthew A Pettengill; Sweta Joshi; Ning Li; Ilana Bergelson; Tobias Kollmann; David J Dowling; Ofer Levy
Journal:  Front Immunol       Date:  2018-01-24       Impact factor: 7.561

Review 7.  Frequently asked questions on seven rare adverse events following immunization.

Authors:  G L D'alò; E Zorzoli; A Capanna; G Gervasi; E Terracciano; L Zaratti; E Franco
Journal:  J Prev Med Hyg       Date:  2017-03

8.  Persistence of Vaccine-Induced Immunity in Preschool Children: Effect of Gestational Age.

Authors:  Anna Bednarek; Małgorzata Bartkowiak-Emeryk; Robert Klepacz; Barbara Ślusarska; Danuta Zarzycka; Andrzej Emeryk
Journal:  Med Sci Monit       Date:  2018-07-23

9.  Vaccination timeliness and associated factors among preterm infants at a tertiary hospital in Uganda.

Authors:  Irene Nakatudde; Joseph Rujumba; Flavia Namiiro; Ali Sam; Jamir Mugalu; Philippa Musoke
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.